Sunshine Biopharma Inc.: Form 10-Q for the period ended Jun 30, 2024
Filed with the SEC on Aug 16, 2024 and accepted by EDGAR at Aug 16, 2024, 17:00 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-04-01 to 2024-06-30 | $9.3m | us-gaap:Revenues |
| Revenue | 6 months2024-01-01 to 2024-06-30 | $16.8m | us-gaap:Revenues |
| Cost of revenue | 3 months2024-04-01 to 2024-06-30 | $6.9m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2024-01-01 to 2024-06-30 | $12.1m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2024-04-01 to 2024-06-30 | $2.4m | us-gaap:GrossProfit |
| Gross profit | 6 months2024-01-01 to 2024-06-30 | $4.7m | us-gaap:GrossProfit |
| Research and development | 3 months2024-04-01 to 2024-06-30 | $436.2k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2024-01-01 to 2024-06-30 | $658.3k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-04-01 to 2024-06-30 | −$1.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-01-01 to 2024-06-30 | −$2.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-04-01 to 2024-06-30 | $245 | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2024-01-01 to 2024-06-30 | $245 | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2024-04-01 to 2024-06-30 | −$343.7k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2024-01-01 to 2024-06-30 | −$321.3k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-04-01 to 2024-06-30 | −$494.3k | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-01-01 to 2024-06-30 | −$1.8m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2024-04-01 to 2024-06-30 | −$9.94 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2024-01-01 to 2024-06-30 | −$43.48 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-04-01 to 2024-06-30 | 49,726 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2024-01-01 to 2024-06-30 | −$7.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Current assets | At period end2024-06-30 | $25.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-06-30 | $29.3m | us-gaap:Assets |
| Current liabilities | At period end2024-06-30 | $5.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-06-30 | $5.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-06-30 | $23.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001683168-24-005846. Last ingested by Listed: Oct 27, 2026, 12:16 ET. Listed shows no prices and gives no investment advice.